2 results
Search Results
Now showing 1 - 2 of 2
Article Factors Influencing the Transition Time From Psoriasis to Psoriatic Arthritis: A Real-World Multicenter Analysis(Springer Heidelberg, 2025) Kilic, Gamze; Kilic, Erkan; Tekeoglu, Ibrahim; Sargin, Betul; Cengiz, Gizem; Balta, Nihan Cuzdan; Nas, KemalTo identify clinical and demographic predictors associated with the timing of transition from psoriasis (PsO) to psoriatic arthritis (PsA), and to compare the characteristics of patients with concurrent PsO-PsA onset versus those with prolonged transition. A multi-center, observational study was conducted using data from the Turkish League Against Rheumatism (TLAR) network including PsA patients fulfilling CASPAR criteria. Patients were categorized into two groups: Group 1 (concurrent PsO and PsA onset within +/- 1 year) and Group 2 (prolonged transition to PsA, > 1 year after PsO). Demographic, clinical, and laboratory characteristics, disease activity, and patient-reported outcomes were compared between groups. Logistic regression was employed to determine independent predictors of prolonged transition. Among 799 patients (mean age 46.8 +/- 12.3 years), 237 (29.7%) had concurrent onset and 562 (70.3%) had a prolonged transition, with a mean PsO-to-PsA interval of 12.9 +/- 9.6 years. Depression (p = 0.005) and fatigue levels (p = 0.011) were significantly higher in patients with prolonged transition to PsA. Multivariate analysis revealed that scalp psoriasis (OR = 7.162), nail psoriasis (OR = 3.270), family history of PsO (OR = 1.813), and enthesitis ever (OR = 2.187) were associated with prolonged transition. Conversely, family history of PsA (OR = 0.421) and older age at PsO onset (OR = 0.957) predicted shorter transition. Prolonged transition from PsO to PsA is influenced by distinct clinical and demographic factors. Scalp/nail psoriasis, family history of PsO, and enthesitis ever may signal higher risk for prolonged PsA onset. Recognizing these markers can support timely referral and intervention, minimizing diagnostic delay and improving long-term patient outcomes.Article Investigation of Human Herpesvirus 8 & Leishmania Species in Malignant Skin Tumours, Psoriasis, Actinic Keratoses, & Seborrheic Keratoses: a Single-Center Experience From Ankara, Turkey(Scientific Scholar Llc, 2025) Bakir, Ayfer; Usluca, Selma; Kartal, Selda Pelin; Alper, MuratBackground & objectives: The role of human herpesvirus-8 (HHV-8) and Leishmania species in the aetiology of malignant skin tumours and proliferative skin diseases remains a topic of debate. This study aims to analyse formalin-fixed, paraffin-embedded (FFPE) skin biopsy samples using polymerase chain reaction (PCR) to determine whether skin lesions caused by HHV-8 and Leishmania spp. resemble malignant and proliferative skin diseases and assess the role of these pathogens in disease aetiology. Methods: In this retrospective, single-center observational study, skin biopsies were collected from 275 individuals diagnosed with malignant skin tumours, psoriasis, actinic keratoses, seborrheic keratoses, and chronic dermatitis. The presence of HHV-8 and Leishmania spp. in biopsy samples was evaluated Results: HHV-8 DNA was not detected in any of the samples using PCR. However, Leishmania spp. DNA was identified in 8.4 per cent of all samples (n=23). No positivity was observed in the control group (P=0.387). Leishmania spp. DNA PCR positivity was most frequently detected in psoriasis cases (32.4%), followed by actinic keratosis (AK) (8.7%), malignant skin tumours (4.2%), and seborrheic keratosis (SK) (3.8%). When the Leishmania positivity rate in individuals diagnosed with psoriasis was compared with that of the control group, the difference was found to be significant (P=0.002). The positivity rate in squamous cell carcinoma (SCC) (7.3%) was higher than in basal cell carcinoma (1.6%). Interpretation & conclusions: The findings in this study suggests that there is no relationship between malignant and proliferative skin diseases and HHV-8. However, Leishmania spp. DNA was detected in 8.4 per cent of all samples. Biopsy-archived samples may be preferred for the differential diagnosis of Leishmania in diseases that do not respond to treatment and in atypical clinical presentations.
